Endocrine · 2026
ATF4 and FGFR4 cooperatively support thyroid cancer progression and CAF-associated tumor-promoting features.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Jinsong, Cai Jiehao, Ruan Weihong
Аннотация
PURPOSE: Aggressive thyroid cancer remains difficult to treat, partly because molecular programs linking malignant behavior to cancer-associated fibroblast (CAF)-related support are incompletely defined. This study investigated whether ATF4 and FGFR4 cooperate in thyroid cancer cells and whether this relationship persists in a CAF-associated context.
METHODS: Stable ATF4 and/or FGFR4 knockdown was established in 8305 C thyroid cancer cells. Proliferation, migration, invasion, apoptosis, cytokine secretion, transcriptomic changes, and xenograft growth were assessed under basal and CAF-conditioned culture conditions.
RESULTS: Silencing ATF4 or FGFR4 reduced 8305 C cell proliferation, migration, and invasion, with the strongest inhibition after combined knockdown. These effects persisted in CAF-conditioned medium and were accompanied by increased apoptosis, reduced IL-6 and TNF-α secretion, and transcriptomic changes involving cell cycle, stress-response, apoptosis, and inflammatory pathways. In vivo, ATF4 and/or FGFR4 silencing suppressed xenograft growth, increased tumor apoptosis, and reduced CAF-associated marker expression.
CONCLUSION: ATF4 and FGFR4 are functionally associated in thyroid cancer progression. Their cooperative program may contribute to cancer cell aggressiveness and to the maintenance of a CAF-associated tumor-promoting microenvironment.
METHODS: Stable ATF4 and/or FGFR4 knockdown was established in 8305 C thyroid cancer cells. Proliferation, migration, invasion, apoptosis, cytokine secretion, transcriptomic changes, and xenograft growth were assessed under basal and CAF-conditioned culture conditions.
RESULTS: Silencing ATF4 or FGFR4 reduced 8305 C cell proliferation, migration, and invasion, with the strongest inhibition after combined knockdown. These effects persisted in CAF-conditioned medium and were accompanied by increased apoptosis, reduced IL-6 and TNF-α secretion, and transcriptomic changes involving cell cycle, stress-response, apoptosis, and inflammatory pathways. In vivo, ATF4 and/or FGFR4 silencing suppressed xenograft growth, increased tumor apoptosis, and reduced CAF-associated marker expression.
CONCLUSION: ATF4 and FGFR4 are functionally associated in thyroid cancer progression. Their cooperative program may contribute to cancer cell aggressiveness and to the maintenance of a CAF-associated tumor-promoting microenvironment.